OTLC · Oncotelic Therapeutics, Inc.
$0.04
+0.01 (+18.00%)
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing.”View the 10-Q filed Aug 13, 2026
Market Cap
$13.73M
Shares
457.51M
OTLC metrics
51 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.04
Market cap
$13.73M
Price action
19 metricsPrice change (1W)
-7.7%
Price change (30D)
-25.0%
Price change (3M)
-40.0%
Price change (6M)
-25.0%
Price change (YTD)
-62.5%
Price change (1Y)
-40.0%
Trailing year
Price change (5Y)
-78.6%
52-week high
$0.11
52-week low
$0.03
Change from 52-week high
-72.7%
Change from 52-week low
+0.0%
Annualized volatility
151.6%
Beta
0.7
RSI (14D)
37.4
Price vs SMA 50
-21.6%
Price vs SMA 200
-45.3%
Avg volume (3M)
252,345
Relative volume
0.6
Average dollar volume
$10,175
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
457.51M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
100.2×
reciprocal yield 1.0%
P / book
0.1
reciprocal yield 1,927.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
1,803.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-9,497.2%
Trailing 12 months
Net margin
-11,290.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$5.72M
Net income (TTM)
$247.58M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
+39.7%
Revenue (TTM)
$137,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.3%
Year over year · more shares
Revenue CAGR (3Y)
-65.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
+289.3%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
93.6%
Return on assets
62.7%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$409,000
Total assets
$394.75M
Total debt
$2.72M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$1.52M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
11 / 100
Insider activity
2 metricsNet insider buying (90D)
$37,832
Insider-sentiment score
85 / 100
Risk flags
1 metricsGoing concern
Flagged